Adhiraj Lanba
Boston Biomedical Research Institute(US)Pfizer (United States)(US)
Publications by Year
Research Areas
Metabolism, Diabetes, and Cancer, Drug Transport and Resistance Mechanisms, Cancer, Hypoxia, and Metabolism, Pancreatic function and diabetes, Peroxisome Proliferator-Activated Receptors
Most-Cited Works
- → A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects(2016)480 cited
- → Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells(2017)111 cited
- → Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)(2015)68 cited
- → FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis(2017)57 cited
- → Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family(2016)39 cited
- → Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism(2016)21 cited
- → Abstract 69: Characterization of the Role of Glycerol-3-phosphate Acyltransferase-3 in Intestinal Lipid Absorption(2014)
- → CCDC 1455314: Experimental Crystal Structure Determination(2016)